## Phospho-SRF (Ser103) Antibody





Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	<b>Reactivity:</b> H M R	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 67	<b>Source/Isotype:</b> Rabbit	UniProt ID: #P11831	Entrez-Gene Id: 6722		
Product Usage Information		<b>Application</b> Western Blotting						
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA and 50% glycerol. Store 20°C. Do not aliquot the antibody.						
Specificity/Sensitivity		Phospho-SRF (Ser103) Antibody detects endogenous levels of SRF only when phosphorylated at serine 103. This antibody cross-reacts with a non-specific protein of approximately 52 kDa.						
Source / Purifi	ication	Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues around serine 103 of human SRF. Antibodies are purified by protein A and peptide affinity chromatography.						
Background		The serum response factor (SRF) is a 67 kDa phospho-protein that, together with auxiliary factors, modulates transcription of immediate early genes containing serum response elements at their promoters (1,2). SRF contains several phosphorylation sites (3), but functional consequences of phosphorylation have not been identified unequivocally. Several growth factor- and calcium-regulated kinases, such as p90RSK and CaM kinase IV, can phosphorylate SRF at Ser103 (4,5), and Ser103 of SRF is also a nuclear target for MAPKAP kinase 2 (6).						
Background R	eferences	1. Treisman, R. (1995) 2. Janknecht, R. et al. 3. Marais, R.M. et al. ( 4. Rivera, V.M. et al. (1 5. Miranti, C.K. et al. ( 6. Heidenreich, O. et a	(1995) <i>Carcinogene</i> 1992) <i>EMBO J</i> 11, 97 1993) <i>Mol Cell Biol</i> 1 1995) <i>Mol Cell Biol</i> 1	<i>sis</i> 16, 443-50. <sup>7</sup> -105. 3, 6260-73. 5, 3672-84.				
Species Reacti	ivity	Species reactivity is d	etermined by testin	g in at least one approve	ed application (e.g.,	western blot).		
Western Blot I	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.						
Applications <b>K</b>	(ey	W: Western Blotting						
Cross-Reactivi	ty Key	H: Human M: Mouse R: Rat						
Trademarks and Patents		Cell Signaling Techno	logy is a trademark	of Cell Signaling Techno	logy, Inc.			
		All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.						
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.						
		approved, cleared, or purpose. Customer sl any manner that conf Customer as the end-	licensed by the FDA hall not use any Pro flicts with its labelin- user and solely for	se Only or a similar labe or other regulatory for duct for any diagnostic o g statement. Products so research and developme urposes, or any purchas	eign or domestic er or therapeutic purp old or licensed by C ent uses. Any use of	ntity, for any ose, or otherwise in ST are provided for FProduct for		

component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.